Author reply to McDonough
Brendan J. Nolan, Ada S. Cheung

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
- —National Health and Medical Research Council 10.13039/501100000925
- —Sylvia and Charles Viertel Charitable Foundation 10.13039/100008717
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLGBTQ Health, Identity, and Policy · Reproductive Health and Technologies · Sexual Differentiation and Disorders
We appreciate McDonough's1 letter but note that it contains frequently debunked disinformation.2 Our Clinical Perspective article ‘Gender affirming hormone therapy for transgender and gender‐diverse adults in Australia’ provides recommendations for the initiation and monitoring of gender‐affirming hormone therapy (GAHT) in transgender and gender‐diverse (trans) adults.3 Despite this, McDonough raises concerns about trans children and youth,1 which is beyond our article's scope. Furthermore, our article is unrelated to the Cass review of gender identity services for children in the United Kingdom, a flawed and unbalanced report inconsistent with established global standards.4
Gender‐affirming care is an evidence‐informed, patient‐centred approach that supports trans individuals in their personal goals of better aligning their physical, psychological and social characteristics with their gender identity.5 It has the goals of improving mental health, reducing gender dysphoria and enhancing overall quality of life, while respecting individual values and bodily autonomy. In contrast to simply ‘accepting the subjective interpretation of gender by a young person’, gender‐affirming care involves comprehensive evaluation of coexisting mental health conditions and facilitating self‐exploration of identity and gender, as well as social and psychological support.5 Some but not all trans individuals request GAHT and/or surgical interventions. Notably, these interventions are associated with improvements in mental health, including reductions in gender dysphoria, depression and suicidality in trans adults6, 7 and youth.8
McDonough's claim that the World Professional Association for Transgender Health (WPATH) is ‘discredited’ relies on a non‐peer‐reviewed source from a conservative Christian lobby group. Gender‐affirming care is supported by not only WPATH but also over 30 professional medical associations, including the Australian Medical Association and the Royal Australasian College of Physicians.9, 10, 11
Similarly, the notion of social contagion or rapid‐onset gender dysphoria is unsubstantiated. The only study suggesting it, based on parental reports rather than direct engagement with trans youth, has been widely criticised and corrected.12 Population data contradict this theory, showing stabilisation of the number of people identifying as trans13 and stable proportions of gender dysphoria diagnoses over time.14
Restricting gender‐affirming care or waiting to find the ‘cause’, as proposed by McDonough, is unethical and harmful and completely disregards the lived experiences and needs of trans individuals, who are not a ‘new disease phenomenon’. Such restrictions increase risks of suicide, depression, anxiety, disordered eating and a diminished quality of life.8, 15, 16, 17, 18, 19, 20
Gender incongruence is not a disorder, nor is it a condition of mental ill health, and it is not comparable to opioid use disorder. Sex steroid formulations used in GAHT are identical to those prescribed to cisgender individuals for the treatment of hypogonadism or menopause and are neither addictive nor harmful.21
The gender‐affirming model of care is supported by multiple studies summarised in our review and here.2, 8, 15, 16, 17, 18, 19 Evidentiary standards for gender‐affirming care should not be subjected to standards that are not applied elsewhere in medicine.4
As for any treatment in medicine, a shared decision‐making approach carefully balancing potential benefits with potential risks should be taken, involving patients, their family, and their treating clinician. Medical interventions should be guided by scientific evidence, clinical expertise and patient‐centred care in accordance with established guidelines from reputable medical organisations, free from political interference. Most importantly, the voices and perspectives of trans individuals must be recognised and respected, rather than dehumanised by efforts to impose rigid gender binaries and norms driven by conservative ideologies.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Mc Donough M . Concern about the ‘gender‐affirming’ treatment approach. Intern Med J 2025; 55: 692–693.10.1111/imj.7004340167138 · doi ↗ · pubmed ↗
- 2Meade NG , Lepore C , Olezeski CL , Mc Namara M . Understanding and addressing disinformation in gender‐affirming health care bans. Transgend Health 2024; 9: 281–287.39385955 10.1089/trgh.2022.0198 PMC 11456759 · doi ↗ · pubmed ↗
- 3Nolan BJ , Cheung AS . Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia. Intern Med J 2024; 54: 1450–1457.39056542 10.1111/imj.16413 · doi ↗ · pubmed ↗
- 4Aaron DG , Konnoth C . The future of gender‐affirming care – a law and policy perspective on the Cass review. N Engl J Med 2025; 392: 526–528.39813640 10.1056/NEJ Mp 2413747 · doi ↗ · pubmed ↗
- 5Coleman E , Radix AE , Bouman WP , Brown GR , de Vries ALC , Deutsch MB et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 2022; 23: S 1–S 259.36238954 10.1080/26895269.2022.2100644 PMC 9553112 · doi ↗ · pubmed ↗
- 6Nolan BJ , Zwickl S , Locke P , Zajac JD , Cheung AS . Early access to testosterone therapy in transgender and gender‐diverse adults seeking masculinization: a randomized clinical trial. JAMA Netw Open 2023; 6: e 2331919.37676662 10.1001/jamanetworkopen.2023.31919 PMC 10485726 · doi ↗ · pubmed ↗
- 7Ireland K , Hughes M , Dean NR . Do hormones and surgery improve the health of adults with gender incongruence? A systematic review of patient reported outcomes. ANZ J Surg 2025 (in press).10.1111/ans.70028 PMC 1210557039973516 · doi ↗ · pubmed ↗
- 8Chen D , Berona J , Chan YM , Ehrensaft D , Garofalo R , Hidalgo MA et al. Psychosocial functioning in transgender youth after 2 years of hormones. N Engl J Med 2023; 388: 240–250.36652355 10.1056/NEJ Moa 2206297 PMC 10081536 · doi ↗ · pubmed ↗
